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                                                                  Introduction
Over the last twenty years, with the advances in molecular biology, the understanding of tumorigenesis 
has reached a stage where novel treatments are being experimented. The present study analyzes the expression 
pattern of p53 and EGFR in glioblastoma multiforme and correlates this to outcome. 
Literature Review
In 1863 Virchow described Glioblastoma multiforme (GBM) as a highly malignant brain tumor of glial 
origin with the worst prognosis of all the brain  tumors17. These tumors are notorious for their rapid invasion 
into neighboring structures of brain along the white matter, perivascular space, subependymal plane or subpial  
plane5,  7.  Glioblastoma  multiforme  accounts  for  12-15%  of  intracranial  neoplasms26 and  50-60  %  of  the 
astrocytic tumors52. The peak incidence is between 45-70 years52, but they also occur in children9. Males are 
more commonly affected than females52. The commonest location is in the cerebral subcortical white matter in 
the following order of frequency - temporal lobe, parietal lobe, frontal lobe and occipital lobe. The typical  
histological  features  include  nuclear  atypia,  microvascular  proliferation,  multinucleated  giant  cells  and 
necrosis17. In the WHO classification it has been allocated a “grade 4” owing to its highly malignant and bizarre  
characteristics.
WHO classification:
WHO classification 17, 19 is more widely accepted than the previously used Kernohan  16 and Ringertz 37 
grading of astrocytomas. The St.Anne/Mayo grading system, based on four criteria (nuclear atypia, mitosis,  
microvascular proliferation and or necrosis) is however both reproducible and predictive of patient survival.  
Comparison of the WHO grading with the St. Anne/Mayo grading is given in Table I. As a general rule the  
grading is based on the area of highest degree of anaplasia, with the assumption that this tumor cell population  
eventually determines the course of the disease. Apart from the histopathological features, the patient’s survival  
also depends on age,  Karnofsky’s  performance score,  tumor location and treatment.   The average survival  
pattern  is  more  than  five  years  for  diffuse  astrocytoma (WHO grade II),  two to  five  years  for  anaplastic  
astrocytoma (WHO grade III) and less than one year for glioblastoma (WHO grade IV).
                   Table 1: Comparison of  WHO grading of Astrocytoma with the St          
                    Anne/Mayo grading system.
In 1940 Scherer described two different types of GBMs, primary GBMs and secondary GBMs38. 
Primary GBMs were those with a shorter duration of symptoms usually less than 3 months, seen in adults  
older than 45 years and with a bad prognosis. Secondary GBMs were those that progressed from a low 
grade tumor through to a high grade astrocytoma, with a longer duration of symptoms, seen in younger  
patients usually less than 45 years of age 15,  31. 
Ohgaki  et  al32 in their study of 715 cases of GBM concluded that  38 patients  had clinical  and 
histopathological evidence of progression from a less malignant precursor lesion and these were diagnosed  
as secondary GBMs. The remaining 677 patients showed either clinical or histopathological evidence of 
highly malignant lesion and were classified as primary GBMs. 
 At present it is increasingly accepted that the two types of GBMs have different genetic pathways 
of evolution18, 32. The primary GBMs are supposed to arise from deregulation of epidermal growth factor 
receptor  pathway15,  16 and  the  secondary  GBMs are  supposed  to  arise  from deregulation  of  cell  cycle 
pathway by mutation of p53 gene which is a tumor suppressor gene  or over expression of p53 protein48, 49. 
Lang et al25 in his study of 65 astrocytic gliomas postulated different genetic pathways leading to GBMs.  
One pathway was characterized by 43 astrocytomas with alteration in p53. GBMs with p53 alterations 
O WHO Grade WHO designation St.Anne/Mayo 
designation
Histological criteria
          I Pilocytic astrocytoma
         II Diffuse astrocytoma Astrocytoma grade 2 One criterion, 
usually nuclear 
atypia
        III Anaplastic 
astrocytoma
Astrocytoma grade 3 Two criteria, usually 
nuclear atypia and 
mitotic activity
       IV Glioblastoma 
multiforme
Astrocytoma grade 4 Three criteria: 
nuclear atypia, 
mitoses, endothelial 
proliferation and/or 
necrosis
represented tumors that progressed from low grade astrocytoma. This variant was more likely to show loss 
of chromosome 17p than tumors without p53 alterations (p<0.04). Seventy five percent of tumors with loss  
of one 17 p allele demonstrated mutation in the  p53 gene. Loss of chromosome 10 was associated with 
progression from anaplastic astrocytoma (13%) to glioblastoma (38%) (p<0.04). Amplification of EGFR 
gene was a rare (7%) but late event in tumor progression (p<0.03). A second pathway was characterized by 
six astrocytomas without p53 alterations and represented clinically denovo high grade tumors. These tumors  
were  more  likely  to  show  amplification  of  EGFR  gene  (83%).  60%  of  them  also  showed  loss  of  
chromosome  10;  loss  of  chromosome  17p  was  infrequent  in  this  variant.  In  addition,  there  were  16  
astrocytomas with none of the known genetic changes. He concluded that GBMs were a heterogeneous  
group of tumors that probably arose via multiple genetic pathways.  
Hayashi  et  al12,  in  their  study of 70 patients  of GBM noted that  EGFR amplification  and  p53 
mutation were mutually exclusive (p<0.0001, Fisher exact test). They also noticed that  p53 mutation was 
seen  in  younger  patients  and  EGFR amplification  was  seen  in  older  patients  and  tumors  with  EGFR 
amplification behave in a more aggressive manner.   Watanabe et al 51  in their study also found that p53 and 
EGFR mutations were exclusive for secondary and primary GBMs respectively.
Recent reports revealed that the survival after surgery, radiotherapy and chemotherapy is better in 
secondary GBM compared to primary GBM. 
Cell  growth and proliferation are enhanced by ‘proto-oncogenes’ such as,  the epidermal growth 
factor receptor gene, whereas genes which restrict abnormal cell division and growth are termed ‘tumor 
suppressor genes’ such as, p53. 
p53 is a tumor suppressor gene located on  the short arm of chromosome 17p.13.3. The protein is  
primarily a sequence specific transcriptional activator. It binds to responsive elements within the genome 
and activates the transcription of genes residing in the vicinity of these binding sites. The proteins encoded  
by  p53 target  genes,  whose  number  is  probably  in  the  hundreds,  contribute  in  multiple  ways  to  the 
biological effects of p53. The biological outcome of p53 activity includes apoptosis, inhibition of cell cycle,  
senescence, differentiation and accelerated cell repair. p53 is believed to reside in a biologically latent state 
in the absence of cellular stress, although the exact biochemical nature of this latency is under debate. When 
the cells experience a variety of stress conditions,  p53 becomes activated. Activation involves a marked 
increase  in  cellular  p53,  as  well  as  qualitative  changes  that  endow each p53 molecule  with  improved 
capabilities to modulate gene  expression and alter the cell phenotype. The types of stress that promote p53 
activation include many conditions associated with cancer initiation and progression, such as direct DNA 
damage, chromosomal aberration, illegitimate activation of oncogenes, hypoxia, telomere shortening and 
more33. p53 expression is studied by quantifying the  p53 protein by immunohistochemical studies by biotin  
avidin peroxidase method  and p53 gene mutation is identified by studying loss of heterozygosity, southern 
blot analysis28 .
EGFR
Epidermal growth factor receptor (EGFR) is a transmembrane receptor that binds to extracellular  
ligands  such  as  epidermal  growth  factor  and  transforming  growth  factor  alpha  and  transduces  mitotic 
signals1.  It  has  an  external  ligand  binding  site,  a  trans  membrane  component  and  an  intracellular  
cytoplasmic region which modulates signal transduction pathways by activation of kinase pathway. EGFR 
amplification  has  been  identified  as  a  genetic  hallmark  of  GBMs.  The  predictive  value  of  EGFR 
amplification  has  been  unclear.  Layfield  et  al27,  have  noted  that  EGFR  identification  by 
immunohistochemistry correlates well with identification of EGFR gene amplification by fluorescence in  
situ hybridization (FISH).
Factors affecting glioblastoma multiforme prognosis:
Age
Pre operative Karnofsky’s performance score
Location of the lesion
Extent of the excision
Histopathology
        a) Giant cells
        b) Gemistocytes
        c) Oligodendroglial component 
d) Cystic component
di)
Radiation
Chemotherapy
Genetic factors
Age:
 Patients with younger age have a better prognosis compared to the older patients. It has also been 
found that secondary GBMs are seen in younger patients whereas primary GBMs are seen in the older age  
group. Shrieve et al42, in their study of 78 patients with GBM reported that patients less than 40 years of age 
have a median survival time of 48.6 months compared to patients older than 40 years who’s median survival 
time was 18.2 months (p<0.0001). Korshunov et al21 and Lamborn et al24  also reported an age < 40 years as an 
important prognostic indicator of better survival. Ohgaki et al32 in his study also showed by both univariate 
and multivariate analyses that old age is a significant predictor of poor survival in GBMs. The cut off age in  
his series was 50 years, with younger patients (<50 years) having a significantly longer survival (median 8.8  
months) than older patients (>=50 years; median, 4.1 months; p<0.0001). Sneed et al 45 in their study on 159 
glioblastoma multiforme patients noticed that nine patients between 18 and 29.9 years of age had a 3 years 
survival probability of 78+/- 14%. The 64 patients between 30 and 49.9 years of age had a 3 year survival  
probability of 29+/-6% and 86 patients >= 50 years had a 3 years survival probability of 6+/-3%. Stark et al 46, 
in their study of 267 cases of GBM noted that age below 61 years was significantly associated with prolonged  
survival (p<.001).
Pre Operative Karnofsky’s performance status score:
Karnofsky’s performance score is a good prognostic indicator. Layfield et al27 in their study of 34 
patient of glioblastoma multiforme noted that those with a higher Karnofsky’s performance status score  
survived longer. Stark et al46, in their study of 267 patients of GBM showed that a pre operative Karnofsky’s  
performance status score of 70 or more was a good prognostic indicator (p<.001). Lacroix et al23 in their 
study of  416 patients with GBM also reported a better prognosis with good Karnofsky’s performance status 
score. 
Duration of symptoms:
It is believed that patients with primary GBM have a shorter duration of symptoms, usually less 
than three months, compared to patients with secondary GBM  It has also been reported that patients with a 
shorter duration of symptoms have a worse prognosis2. 
Location of lesion:
Superficial lesions have a better prognosis compared to the deep seated lesions. This is due to the 
wider excision that can be performed on superficial lesions. Lacroix et al 23,  in their study of  416 patients of 
GBM observed that tumors located in the eloquent brain were associated with a shorter duration of survival  
but this effect was lost in multivariate analysis. He did not find a survival difference between deeply located  
tumors and superficial tumors. 
Extent of excision:
Patients who have a radical excision have a better prognosis compared to the patients who have a 
partial excision or biopsy.. Lacroix et al23,  in  their study of 416 patients with GBM found that there was a 
significant  survival advantage associated with resection of 98% or more of the tumor volume, median  
survival was 13 months compared with 8.8 months for resection less than 98% (p<0.0001). Kreth  et al 22, in 
their study of 57 patients reported a median survival time for resection followed by radiotherapy group of  
39.5 weeks as compared with 32 weeks for biopsy followed by radiotherapy group. This difference was  
however not statistically significant. Barker et al4, in their study of 301 patients with GBM found that the 
extent  of  resection  and  the  immediate  response  to  radiation   therapy  correlated  with  survival  both  in  
univariate analysis and multivariate Cox model after correction for age and KPS (p<0.0001 for radiation  
response and p=0.04 for extent of resection). Stark et al46, in their study of 267 cases of GBM also reported 
that total tumor excision was significantly associated with prolonged survival (p=.014). 
Histopathology of the lesion:
Giant cell:
             Homma et al13, in their study of 403 patients of GBM showed that GBMs containing  > 5 % 
multinucleated cells had a poorer survival. However, patients with giant cell glioblastoma had a longer  
survival (12.4+16.2 months) than those with other forms of GBM (8.4+-7.9 months), but this difference was 
not significant. (p=0.105). Shinojima et al41, in their study of 113 patients of GBM six patients survived 
more than five years. Incidentally three of the six were diagnosed as giant cell GBM. 
Gemistocytes:
Homma et al13, in their study had found no correlation between the presence of gemistocytes and  
prognosis. When present in large numbers, particularly in a patient known to have a pre existing glioma,  
these cells may represent a lower grade precursor lesion within a secondary glioblastoma. Reis et al 36, in 
their study mention that gemistocytic variants of low grade astrocytoma are prone for rapid progression to  
anaplastic astrocytoma and GBM.   
Oligodendroglial component:
Oligodendroglial component is present in about 20% of GBMs13. Patients with GBM containing an 
oligodendroglial component are significantly younger13. In a study by Homma et al13, the median survival of 
GBM  patients  with  an  oligodendroglial  component  was  8.1  months  and  for  those  without  an 
oligodendroglial component it was 6 months. Pinto et al34, in their study on 47 cases of GBM also detected 
a longer survival in patients with an oligodendroglial component. Vordermark D et al 50, in their study of 10 
cases of GBM with an oligodendroglial component showed that these patients had a better response to  
chemotherapy and radiation therapy compared to those without this component.
Cystic component
Maldaun et al29, in their study of 22 cases of cystic GBM found that the median survival time after  
surgery was 18.2 months and that at 2 years 43 % of the patients were still alive. In patients with non cystic  
GBM the median survival time was 14.3 months and only 16 % of patients were alive at 2 years. The 
median time for tumor recurrence was 7.6 months in patients harboring cystic GBMs and 4.2 months in the 
non cystic GBM group. Though there was a trend towards better prognosis for cystic GBMs there was no 
statistical significance. 
Radiation therapy:
At present multimodality therapy is favored for GBM which includes surgery, radiotherapy and  
chemotherapy. Barker et al3, studied 301 GBM patients and concluded that younger patients (p=0.006), high 
pre operative Karnofsky’s performance score (p=0.027) and more extensive surgical resection (p=0.028)  
predicted  better  radiation  response  in  univariate  analyses.  Almost  similar  responses  were  noted  in 
multivariate analyses. They had in an earlier study also reported similar findings.27. Fazeny et al10  in their 
study of 98 GBM patients noted that the  median survival time for patients who underwent only stereotactic  
biopsy was 9 weeks, 13 weeks for patients  who underwent biopsy and radiotherapy and 31 weeks for  
patient who received radiation and chemotherapy(p<=0.001) following biopsy.
Chemotherapy:
Chemotherapy improves the survival marginally when combined with surgery and radiation. Combs 
et al8, in their study on 53 patients diagnosed to have GBM concluded that the overall survival is relatively 
long for patients who had radiation therapy and chemotherapy  compared to the survival times reported for  
radiation alone. Fine  et al11, in a meta analysis of 16 randomized clinical trials, which included more than 
3000 patients treated between 1975 and 1989, demonstrated a survival benefits  for those patients with 
malignant  glioma  treated  with  radiation  and  adjuvant  chemotherapy  compared  to  those  treated  with  
radiation alone. Stupp et al47 in their study have shown that addition of temozolomide to radiation therapy  
confers a meaningful survival advantage compared with post operative RT alone in GBM. As mentioned 
previously Fazeny et al10 has shown that patients with chemotherapy and radiation therapy survived better 
compared  to  patients  who underwent  biopsy  alone  and  patients  who  underwent   biopsy  and radiation  
therapy (P= 0.001). Mirimanoff et al30 in their study of five hundred and seventy three patients subjected 
219 patients for postoperative radiotherapy and chemotherapy with a median survival time of 15 months. 
261 patients who underwent radiation therapy alone had a median survival time of 12 months. 
Genetic factors:
There are various genetic factors considered to affect the prognosis of patients with GBM. There are  
conflicting reports on the prognostic influence of p53 mutation or over expression and EGFR amplification 
or over expression. Kleinschmidt et al20,  in their study of 38 patients with GBM observed that there was a 
shorter  patient  survival  with  extensive  necrosis,  extensive  expression  of  p53  and  absence  of  EGFR 
amplification. None of these factors however reached statistical significance. Homma et al 13 in their study 
of 420 cases of GBM correlated key genetic alteration and clinical outcome. EGFR amplification and p16  
homozygous deletion were significantly more frequent in small cell glioblastomas than in non small cell 
glioblastomas.  Multivariate  analysis  with  adjustment  for  age  and  gender  showed  that  small  cell  
glioblastoma had frequent EGFR amplification and p16 deletion but infrequent PTEN mutations. Simmon 
et al43, and Smith et al44 showed that there was no association between p53 expression and outcome in 
patients with GBM,.  Schmidt et  al39,  in their study of 97 patients suggested that p53 expression was a 
favorable  prognostic  indicator  of  GBM  (p=0.0085).  Ohgaki  et  al32,  in  their  population  based  study 
suggested that  p53 mutation was predictive of favorable prognosis in univariate analysis. Birner et al 6 in 
their study of 114 patients of primary GBM noted that there were 29 patients with p53 protein expression.  
These patients were significantly younger and had a significantly longer survival in univariate analysis  
(p=0.0399, log rank test). Reavey-Cantwell et al33  in their study of 32 patients of glioblastoma on the other 
hand concluded that there was no prognostic significance of p53 expression. 
 EGFR amplification has been associated with poorer survival in patients with GBM14, 51. Shinojima 
et al40, reported that EGFR amplification was a unfavorable predictor for overall survival in glioblastoma 
patients but that the EGFR gene status was a more significant prognostic factor in younger patients (<60  
years). Simmons et al43  , also reported that EGFR over expression was associated with poorer survival of 
GBM patients younger than the median age and that EGFR over expression was negatively associated with  
survival in cases without TP 53 mutation. Smith et al44 on the other hand, reported that EGFR amplification 
was a predictor of longer survival only in older glioblastoma patients,  However, Ohgaki et al 32, in their 
study on 715 cases of GBM showed that there was no correlation between EGFR amplification and survival 
at any age.   Schmidt et al39 in their study of 97 patients also showed a lack of predictive value of EGFR 
amplification. This was further corroborated by a meta-analysis of seven previous studies which did not  
detect a significant predictive value of EGFR amplification15. 
                                                 Aims and Objectives
     1.   To determine the expression pattern of p53 and EGFR  in  
           glioblastoma multiforme.
 
    2.  To determine whether the above two markers predict the biological     
          behavior of glioblastoma multiforme. 
 
                                                    
                                                           Hypotheses
1) Younger patients show p53  over expression and older patients show
            EGFR over expression (age >= 50 yrs versus  < 50yrs).
2) EGFR is over expressed in patients with shorter duration of symptoms   
            and p53 is over expressed in patients with longer duration of 
            symptoms.  (< 3months versus  >3 months)
3) Males are more likely to have EGFR overexpression and females are more 
            likely to have p53 overexpression.
4) EGFR expression is associated with poorer survival compared to p53 
            expression.
5) Co expression of p53 and EGFR are associated with poorer survival as
            compared to lack of expression of both p53 and EGFR.   
                                                Material and methods
In a prospective study, fifty eight patients who were diagnosed with GBM  from June 2003 to Sept  
2004 were included. Age, gender and duration of symptoms were recorded in the data sheet. The clinical  
symptoms were grouped as seizures, focal neurological deficits and features of raised intracranial pressure.  
Pre operative Karnofsky’s  performance status score  and post  operative Karnofsky’s  performance status 
score were noted. All patients had pre operative CT scan or MRI of the brain. The location of the lesion was  
noted. The size of the lesion was measured in centimeters. The presence of necrosis and mass effect was  
also noted. 
Operative details:
All patients underwent open excision except one who underwent a stereotactic biopsy. The surgery  
was classified as radical excision, subtotal excision, partial excision and biopsy based on the post operative  
imaging (contrast CT or contrast MRI). Radical excision was defined as gross total removal of tumor. Sub  
total excision was defined as excision of 90% of the tumor and partial excision was defined as removal of  
less than 90% of tumor and in biopsy as those where tumor tissue sampled for histological diagnosis.  
Treatment protocol:
As mentioned above, all patients underwent open surgery with the exception of one patient who had 
stereotactic  biopsy.  This  was  followed  by  radiation  therapy  in  the  form  of  conventional  radiation  or  
conformal radiation therapy. 180 cGy was given five days a week for a period of 31 days over 6 weeks to a  
total  dose of 5580 cGy.  All  patients  were  given chemotherapy with CCNU or Temozolomide or PCV.  
CCNU  was  given  at  a  dose  of  200  mg/m2  in  single  dose  every  six  weeks  for  six  cycles  and 
Temozolomide(TMZ) was given at a dose of 75mg/m2 daily concomitantly during RT and adjuvant TMZ 
was given at 150-250 mg/m2 in gradually increasing doses for 5days every 28 days for 6 cycles. PCV was 
given  for  patients  with  glioblastoma  with  oligodendroglial  component  who  were  not  responsive  to 
temozolomide. 
Follow-up:
Follow up was obtained either through patient record of direct visits to the clinic or through letters.  
Follow up was obtained in 34 patients. 
Histopathology and immunohistochemistry:
All  the cases were reviewed histopathologically  and the diagnosis  of Glioblastoma multiforme, 
WHO  grade  IV  was  confirmed.  A  representative  section  was  chosen  in  each  case  and 
immunohistochemistry for p53 protein and EGFR protein was done by the avidin biotin peroxidase method  
using  monoclonal  antibodies  to  these  two  proteins.  p53  (DAKO ppts)  and  EGFR (DAKO ppts).  The 
protocol used in given in Appendix I.  Negative and positive controls were included. p53 was considered 
positive if there was evidence of nuclear staining and EGFR positivity was seen as diffuse membrane  
staining.
Statistical method:
The data was analyzed using cross tabulations.  Survival analysis was done using Kaplan Meier  
graphs in patients with follow up. 
Results
There  were  58  cases  of 
GBM  treated  in  this 
hospital  that  were 
included  in  this  study 
(Fig 1&2 and Table 2)
Fig 1: Shows a gadolinium enhancing lesion of the dominant frontal lobe with extension into the ventricles  
and the frontal opercula.
Fig 2: Post operative scan of the same patient showing radical excision with no tumor residue. This patient  
did not have speech deficit post operatively. 
                                                          
                                                                 TABLE 2. Data of all 58 study patients.
NA       -  Not Available ; CCNU – Carmustine; PCV    – Procarbazine, Carmustine, Vincristine; TMZ   – Temozolomide
Histopathology of GBM:
Sno EGFR
P53 
status
Follow up 
duration Sex Age
Preop 
KPS Chemo RT dur-symp
1 + + 17 M 56 90 TMZ Y 2
2 + + NA M 42 30 NA NA 2
3 + + 17 M 37 60 NA Y 5
4 + + 20 F 35 80 NA Y 5
5 + + NA M 67 60 NA NA 8
6 + + NA F 28 70 NA NA 24
7 + + 11 M 55 80 TMZ Y 10 days
8 + - NA F 53 60 NA NA 1
9 + - 3 M 55 60 NA Y 2
10 + - 13 M 50 70 CCNU Y 2
11 + - 16 F 51 70 CCNU Y 2
12 + - NA M 46 80 NA NA 2
13 + - NA M 44 50 NA NA 2
14 + - 17 F 30 60 CCNU Y 3
15 + - 18 M 55 70 NA Y 3
16 + - NA M 35 90 CCNU Y 3
17 +      - NA M 42 80 NA NA 3
18 + - 24 F 37 80 NA Y 4
19 + - NA M 38 70 NA NA 5
20 + - 4 M 38 80 TMZ Y 6
21 + - 10 F 55 50 TMZ Y 12
22 + - NA M 48 60 NA NA 20 days
23 + - 6 M 54 60 TMZ Y 5days
24 - + 16 M 52 70 TMZ Y 1
25 - + NA M 28 90 NA NA 1
26 - + 5 M 65 70 CCNU Y 2
27 - + 10 M 35 60
CCNU/P
CV Y 2
28 - + 23 M 59 80 CCNU Y 2
29 - + 32 M 23 100 CCNU Y 2
30 - + NA M 27 60 NA NA 2
31 - + NA M 37 60 NA NA 2
32 - + NA M 36 70 NA NA 2
33 - + NA F 40 60 NA NA 2
34 - + 9 M 33 90 NA Y 3
35 - + 6   M 28 80 NA Y 3
36 - + 21 M 62 70 CCNU Y 3
37 - + NA M 35 80 NA NA 3
38 - + 4 M 43 60 NA Y 5
39 - + 5 M 60 80 NA Y 5
40 - + 20 F 35 70 CCNU Y 5
41 - + 10 M 38 70 CCNU Y 6
42 - + 16 F 13 90 CCNU Y 12
43 - + NA M 35 60 NA NA 18
44 - + NA F 49 60 CCNU NA 15 days
45 - + 3 M 7 80 CCNU Y 7days
46 - - 3 F 59 80 CCNU Y 1
47 - - 10 M 55 80 TMZ Y 1
48 - - NA M 35 30 NA NA 1
49 - - 22 M 31 80 TMZ/CCNU/PCV Y 2
50 - - NA M 60 80 NA NA 2
51 - - NA F 45 60 NA NA 2
52 - - 24 M 32 70            CCNU/PCV Y 3
53 - - 12 M 45 70 CCNU Y 4
54 - - NA M 17 50 NA NA 6
55 - - 10 M 55 80 NA Y 24
56 - - NA M 68 70 NA NA 12 days
57 - - 5 F 55 60 CCNU Y   14 days
58 - - NA M 25 50 NA NA 14 days
All 58 cases showed the classical histological features of a glioblastoma multiforme, which included 
mitotic activity, necrosis and endothelial proliferation (Fig 3-7).
Fig 3
Glioblastoma multiforme with marked nuclear atypia, bizarre nuclei and mitotic figures (H&E X 90).
Fig 4
Glioblastoma multiforme with multinucleated giant cells and bizarre forms (B) (H&E X400).
Fig 5
Glioblastoma multiforme with numerous mitotic figures (M) (H&E X400).
Fig 6
Vascular (endothelial)  proliferation(E) in glioblastoma multiforme (H&E X400).
Fig 7
Palisading necrosis (N) in glioblastoma multiforme (H&E X 400).
Immunohistochemistry revealed that 7 cases were positive for both EGFR and p53, 16 were EGFR 
positive and p53 negative, 22 were EGFR negative and p53 positive and 13 were negative for both EGFR  
and p53 (Fig 8&9).
Fig  8a  -  Nuclear  positivity  for  p53(P)  on  immunohistochemistry  in  cases  of  glioblastoma  multiforme 
(400X).
Fig 8b -  Nuclear positivity  for p53 (P)  on immunohistochemistry in  cases of glioblastoma multiforme 
(400X).
Fig 9a - Strong cytoplasmic membrane staining (P) in cases of glioblastoma with EGFR overexpression  
(400X)
Fig 9b - Strong cytoplasmic membrane staining (P) in cases of glioblastoma with EGFR overexpression  
(400X).
                        TABLE 3. Data of  the 34 patients with follow up details.
Hypothesis 1: 
Younger patients (< 50yrs) show p53  overexpression and older patients (> 50 
yrs) show EGFR over expression  
Sl no EGFR
p53 
status
Survival 
(months) Sex Age
Preop 
KPS Chemo RT
Duration 
of symp
Death/recurred/n
o recurrence
1 + +           17 M 37 60NA Y 5 Died
2 + +           20 F 35 80NA Y 5 Died
3 + +           17 M 56 90TMZ Y 2 Died
4 + +          12 M 55 80TMZ Y 10 days Died
5 +  -           13 M 50 70CCNU Y 2 Died
6 +  -             3 M 55 60 Y 2 Died
7 +  -             8 M 54 60TMZ Y 5 days Died
8 +  -  17F 30 60CCNU Y 3 Died
9 +  -           24 F 37 80NA Y 4 Died
10 +  -          10 F 55 50TMZ Y 12 Died
11 +  -           16 F 51 70CCNU Y 2 Died
12 +  -             4 M 38 80TMZ Y 6 Recurred
13 +  -           18 M 55 70NA Y 3 Recurred
14  - +             4 M 65 70CCNU Y 2 Died
15  - + 21M 62 70CCNU Y 3 Died
16  - +          16 M 52 70TMZ Y 1 Died
17  - +            5 M 60 80NA Y 5 Died
18  - +             4 M 43 60NA Y 5 Died
19  - +           20 F 35 70CCNU Y 5 No recurrence
20  - +           23 M 59 80CCNU Y 2 No recurrence
21  - +           16 F 13 90CCNU Y 12 No recurrence
22  - +           10 M 28 80NA Y 3 No recurrence
23  - +           10 M 38 70CCNU Y 6 No recurrence
24  - +           32 M 23 100CCNU Y 2 No recurrence
25  - +          13 M 33 90NA Y 3 Recurred
26  - +           10 M 35 60
CCNU/
PCV Y
2 Recurred
27  - +            3 M 7 80CCNU Y 7 days Recurred
28  -  -             3 F 59 80CCNU Y 1 Died
29  -  -           10 M 55 80TMZ Y 1 No recurrence
30  -  -          24 M 28 70
CCNU/
PCV Y
3 Recurred
31  -  -          10 M 55 80NA Y 24 Recurred
32  -  -           22 M 31 80
TMZ/CC
NU/PCVY
2 Recurred
33  -  -             6 F 55 60CCNU Y 14 days Recurred
34  -  -           12 M 45 70CCNU Y 4 Recurred
It was found that there was a significant association of p53 overexpression with patients age of < 50 
yrs (p=0.01) (Table 4).   In older patients of age >50 yrs there was however no significant difference in the  
expression of p53 or EGFR (p= 0.39) (Table 5).
TABLE 4: p53 and EGFR expression in patients  below 50 years of age (n=37).
P53
+ -
EGFR + 4 9
- 17 7
P= 0.01; Odds ratio- 0.81;  CI - 0.03, 0.97
TABLE 5: p53 and EGFR expression in patients above 50 years of age.(n=21)
P53
+ -
EGFR
+ 3 7
- 5 6
P= 0.39; Odds ratio – 0.51; CI – 0.06,4.29
Hypothesis 2:
 EGFR is over expressed in patients with shorter duration of symptoms (<3months)  and p53 is over  
expressed in patients with longer duration of symptoms ( >3 months)
The present study suggests that p53 is over expressed in patients with shorter duration of symptoms  
(p=0.005) (Table 6) There is no significant over expression of p53 or EGFR in patients with longer duration 
of symptoms (p=0.34). (Table  7)
TABLE 6:  p53 and EGFR expression in patients with less than 3 months of symptoms. (n=33)
P53
+ -
EGFR + 2 10
- 14 7
P = 0.005; Odds ratio – 0.10; CI -  0.01- 0.72
TABLE 7: p53 and EGFR expression in patients with more than 3 months of symptoms. (n=25)
P53
+ -
EGFR + 5 6
- 9 5
P= 0.34; Odds ratio – 0.46; CI – 0.07, 3.05
Hypothesis 3:
Males are more likely to have EGFR over expression and females are more likely 
to  have p53 overexpression. 
In this study p53 overexpression was significantly associated with the male patients.  (p=0.003)  
Table 8.  The female patients did not have a significant  predilection for either p53 or EGFR over expression 
(p=0.28), Table 9.
TABLE 8: p53 and EGFR expression in male patients  (n=44).
P53
+ -
EGFR + 5 11
- 18 10
P=0.03; Odds ratio – 0.25; CI – 0.05, 1.11
TABLE 9: p53 and EGFR expression in female patients. (n=14)
P53
+ -
EGFR + 2 5
- 4 3
P=0.28; Odds ratio – 0.30; CI – 0.02, 4.29.
Hypothesis 4:
EGFR expression is associated with poorer survival compared to p53 expression.
Although patients with EGFR over expression had a shorter overall survival than patients with p53 
overexpression, this was not statistically significant (p=0.39).
GRAPH 1: Survival pattern of patients with tumors that are  only p53 positive or only EGFR positive .
Hypothesis 5:
Co 
expression  of  
both  p53 and 
EGFR  are 
associated 
with  poorer  
survival  as  
compared  to  
lack  of  
expression  of  
both  p53 and 
EGFR. 
Although patients with both p53 overexpression and EGFR over expression had a shorter duration 
of survival this was not statistically significant.(p=0.79). 
GRAPH 2: Survival pattern of patients with p53 & EGFR positive and p53 & EGFR negative patients.
Survival analysis for P53 only +ve and EGFR only +ve
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                                                             Discussion 
Glioblastoma multiforme (GBM) is notorious for its rapid growth and local invasion. The main stay  
of the current treatment modality is radical excision followed by radiation therapy and chemotherapy. With  
all the available treatment modalities the expected mean survival time is 12 months. The various factors that  
influence the  prognosis  of  GBM are  age of  the  patient,  pre  operative  Karnofsky’s  performance  score,  
location  of  the  lesion,  size  of  the  lesion,  extent  of  excision,  histological  type,  radiation  therapy  and  
chemotherapy. Further primary GBMs (de novo) has a poorer prognosis compared to secondary GBMs 
(evolved from low grade astrocytoma).
                      The concept of primary and secondary GBM was first observed by Scherer, a German  
pathologist in 194038. Initially it was based on duration of clinical symptoms. As the understanding evolved 
there were attempts to confirm this concept with histopathological and genetic correlations. The last two  
decades saw an exhaustive attempt in identifying the genetic alteration underlying primary and secondary  
glioblastoma.
There are two different genetic pathways attributed to the development of primary and secondary  
glioblastomas. The EGFR pathway for primary glioblastomas and p53 pathway for secondary glioblastomas 
which was proposed by Kleihues et al in 199918 .   p53 is a cell  cycle regulator protein which directly 
regulates cell cycle by activating transcription and EGFR is a epidermal growth factor receptor protein 
which indirectly regulates cell cycle through the kinase pathway. 
In the present study we compared the p53 and EGFR expression with age of the patient, duration of 
symptoms and gender. We also analyzed the survival pattern of GBM patients  in various genetic groups.  
Primary GBMs are generally associated with EGFR amplification and are seen in older patients, on 
the  contrary  secondary  GBMs  are  seen  in  younger  patients  and  are  more  often  associated  with  p53 
mutations5.   
                  Of the 58 patients 33 (56.89%) patients had symptoms less than three months and 25 (43.10%)  
patients had symptoms more than three months. There were 21(36.20%) patients who were more than 50 
years of age and 37 (63.79%) patients who were less than 50 years of age. 
It is said that primary glioblastoma are seen in patients with a shorter duration of symptoms and 
secondary glioblastomas are seen in patients with longer duration of symptoms53. If duration of symptom is 
considered an indicator of the tumor being a primary or secondary glioblastoma, then in this study the  
finding of the patients with shorter duration of symptoms being p53 positive, contradicts the general theory 
that primary GBMs usually associated with EGFR over expression, have a shorter duration of symptoms.  
There was no association of longer duration of symptoms with p53 and EGFR expression. 
In the present study p53 over expression was significantly associated with patient age less than 50 
years. However an age of > 50 years was not associated with p53 or EGFR over expression. Watanabe et  
al51 in their study showed 55 years as the mean age of primary GBMs and 39 years as the mean age of 
secondary GBMs. In the present study the mean age of patients with EGFR over expression was 45.2 years  
and the mean age of patients with p53 over expression was 38.86 years.
Louis DN et al28 have shown that secondary GBMs are more frequently seen in women. In this 
study the reverse was found true with significant number of patients with p53 overexpression in the male  
group.
On  comparing  the  survival  pattern  for  patients  with  either  p53  overexpression  or  EGFR over  
expression, although patients with EGFR over expression had a shorter overall survival than patients with  
p53 overexpression,  this  was  not  statistically  significant.  The  mean  survival  duration  was  12  months.  
Survival analysis of patients who were both p53 and EGFR positive and both p53 and EGFR negative, also  
showed no significant difference in survival duration, although patients with both p53 overexpression and 
EGFR over expression had a shorter duration of survival.
The findings in the present study are in keeping with those reported by  Simmon et al 44, Smith et al44 
and Reavey-Cantwell et al35 who concluded that there is no correlation between the p53 expression and 
prognosis. It is however contradictory to that of Schmidt et al39, Ohgaki et al32 and Birner et al6 who found 
that p53 over expression is a favorable prognostic indicator. 
Similarly,  although  Hurtt  MR  et  al14,  Torp  SH  et  al49,  Shinojima  et  al40  found  that  EGFR 
amplification was associated with poorer prognosis, the result of the present study is similar to the meta  
analysis  of   Huncharek  M  et  al15 and  Ohgaki  et  al32 which  showed  no  association  between  EGFR 
amplification and prognosis. 
As mentioned above although not statistically significant it was found in this study that patients 
with both p53 and EGFR over expression survived for a shorter period of time as compared to those with  
both  genetic  factors  negative.  The  present  study  had  fifty  eight  patients  with  follow  up  information  
available on a little over 60% of patients. Further studies on a larger cohort of patients are indicated to  
conclusively determine whether p53 overexpression and EGFR over expression affect prognosis in patients 
with glioblastoma multiforme.
                 
                                                         Conclusions
1. There was a significant association of p53 overexpression with patient’s age of < 50 yrs. In older patients  
of age >50 yrs there was, however, no significant difference in the expression of p53 or EGFR.
2. Contrary to the second hypothesis  p53 overexpression is seen in patients with a shorter duration of  
symptoms (< 3 months) and there is no correlation between a longer duration of symptoms (>3months) and  
p53 or EGFR expression.
3. There were a significant number of male patients who were p53 positive.  This contradicts the third  
hypothesis. 
4. There was no significant survival difference between patients with either p53 or EGFR over expression. 
5.  There  was  no  significant  difference  in  survival  between  patients  with  both  p53  &  EGFR positive 
compared to patients with both p53 & EGFR negative. 
The present study’s attempt to delineate between primary and secondary GBMs based on genetic 
alterations  based  on  the  existing  literature  and  analytical  knowledge  showed  that  there  is  no  definite  
correlation to categorically classify GBMs to redefine the treatment protocol. 
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                                                         Appendix 1
Peroxidase conjugate avidin method for paraffin sections.
1) Sections are cut at approximately 5 microns, floated on poly L-lysine coated slides & left at 37 
degree overnight.
2) Do not allow slides to dry at any stage of procedure.
3) Carry out the steps of incubation with antibody in AC room.
4) Use appropriate control for each antibodies tested.
Procedure:
1) Dewax section in xylene and bring to water.
2) Transfer those sections which do not need trypsinisation to dish containing TRIS buffered saline 
(pH7.6) (TBS)
3) Trypsinisation
a) Drain off tap water
b) Transfer into preheated dish containing distilled water in 37 degree water bath.
c) Leave for 10 min to attain temperature.
d) Transfer into preheated trypsin solution at 37degree. Allow digestion was 10 min.
e) Stop digestion by running tap water for 5min and then transfer to TBS.
4) Rinse twice in TBS – 5 min each
5) Drain and cover slides with 
a) Normal human pooled serum diluted1/5 monoclonal
b) Normal swine serum diluted for 1/5 for polyclonal.
c) Incubate for 10min.
6) Drain and cover section with optimally diluted primary antibody. Incubate for 30 min. 
7) Rinse in TBS three times each 5 mins.
8) Drain and cover sections in optimally diluted second layer antibody. Incubate for 30 min.
a) Polyclonal- biotinylated swine antirabbit-dilution 1/100
b) Monoclonal- biotinylated rabbit antimouse-dilution 1/200
9) Rinse in TBS three times 5 min each
10) Block endogenous peroxidase with 0.5%H2O2 in methanol
11) Rinse in TBS three times –3 times 5mins each
12) Drain and cover slides with peroxidase conjugated avidin 1/200. Incubate for 30 min.
13) Rinse in TBS three times 5 min each.
14) Develop sections with freshly prepared diaminobenzidine solution containing H2O2 for 
approximately 10 min. Check positive control to ascertain end incubation.
15) Counter stain with Harris hemotoxylin- approx 10 min.
16) Dehydrate clear and mount in gum dammar.
